Probiotics reduced the incidence of acute diarrhea by 25% in shelter dogs, while omega-3 fatty acids increased lesion response by 29% in dogs with atopic dermatitis. This article compiles key statistics on performance, regulation, and industry trends for pet supplements.
Key Takeaways
- Probiotics reduced the incidence of acute diarrhea by 25% in shelter dogs in a controlled study
- In a study of dogs with atopic dermatitis, omega-3 fatty acid supplementation increased lesion response rate by 29%
- In cats, a veterinary diet with supplementation improved fecal consistency score by 0.6 points over 28 days compared with control
- FDA’s Guidance for Industry #152 states that new animal drugs generally require approval before marketing
- FDA’s feed safety modernization rules include Hazard Analysis and Risk-Based Preventive Controls (HARPC) under 21 CFR Part 507
- The EU Novel Food Catalogue defines foods not consumed to a significant degree before 1997 as novel; novel supplements require authorization
- CBD/CBG products comprised 7% of pet supplement sales in 2023 (industry segmentation)
- E-commerce accounted for 25% of pet product sales in 2023 (channel trend supporting supplements)
- Subscription purchases accounted for 12% of pet product buyers in 2023 (channel trend supporting recurring supplements)
Recent trials and reviews show probiotics, omega 3s, and calming supplements can meaningfully improve pet health.
Related reading
01 · Category
Performance Metrics13 stats
01
Probiotics reduced the incidence of acute diarrhea by 25% in shelter dogs in a controlled study
02
In a study of dogs with atopic dermatitis, omega-3 fatty acid supplementation increased lesion response rate by 29%
03
In cats, a veterinary diet with supplementation improved fecal consistency score by 0.6 points over 28 days compared with control
04
In a controlled study, medium-chain triglycerides improved energy score by 20% in dogs with chronic liver disease
05
In osteoarthritis trials, glucosamine/chondroitin regimens showed a mean improvement of 10–18% in mobility scores (systematic review)
06
In a systematic review, omega-3 supplementation produced a standardized mean difference of -0.41 for inflammatory biomarkers in companion animals (meta-analysis)
07
In a double-blind study, S-adenosylmethionine (SAMe) improved osteoarthritis pain by 55% from baseline in dogs (within-study measure)
08
In a controlled trial, liposomal curcumin reduced paw swelling by 30% in dogs with osteoarthritis compared with placebo
09
In a study of dogs with periodontal disease, probiotic supplementation reduced plaque scores by 20% after 21 days
10
In a trial, beta-glucan reduced illness duration by 2.0 days (from 8.5 to 6.5 days) in stressed shelter dogs
11
In a randomized trial, melatonin reduced anxiety-related behaviors by 40% in dogs during fireworks/novel stressors (within-study behavioral outcome)
12
In a randomized controlled trial, L-theanine supplementation reduced stress score by 25% in cats compared with placebo
13
In a controlled trial, hemp-derived cannabidiol (CBD) reduced seizure frequency by 41.3% in dogs with idiopathic epilepsy (Owner-reported outcome)
Interpretation
Performance Metrics Interpretation
Across performance metrics, pet supplements show measurable clinical impact, such as probiotics cutting acute diarrhea incidence by 25% and omega 3 boosting lesion response rates by 29% or improving inflammatory biomarkers with a standardized mean difference of -0.41, indicating strong evidence that these products improve measurable health outcomes.
02 · Category
Regulatory & Safety11 stats
01
FDA’s Guidance for Industry #152 states that new animal drugs generally require approval before marketing
02
FDA’s feed safety modernization rules include Hazard Analysis and Risk-Based Preventive Controls (HARPC) under 21 CFR Part 507
03
The EU Novel Food Catalogue defines foods not consumed to a significant degree before 1997 as novel; novel supplements require authorization
04
EU Regulation (EC) No 178/2002 requires food law to be based on risk analysis including risk assessment
05
EU Regulation (EC) No 767/2009 sets rules on placing feed on the market including labeling requirements relevant to pet feeds/supplements
06
EU Regulation (EC) No 1831/2003 authorizes feed additives only when authorized and included on the Union list
07
In 2022, EFSA received 2,000+ notifications/requests under the EU feed additives framework (includes pet-relevant feed additive approvals)
08
The World Organisation for Animal Health (WOAH) promotes antimicrobial stewardship and publishes guidelines relevant to pet health claims tied to antimicrobial use
09
Canada requires licensed manufacturers for DIN/medicine claims are regulated separately; pet supplements sold as natural health products must follow Natural Health Products Regulations (context)
10
As of 2024, REACH restricts certain chemicals in the EU; manufacturers must ensure compliance for substances potentially used in supplement packaging/ingredients
11
EU RASFF includes 10,000+ notifications annually for food and feed safety; pet supplements as feed can be captured (context)
Interpretation
Regulatory & Safety Interpretation
Across both US and EU frameworks, regulatory oversight is tightening around pre-authorization and risk-based controls, with the US emphasizing approval for new animal drugs and HARPC under 21 CFR Part 507 while the EU requires novel supplement authorization and mandates risk analysis and strict feed labeling under Regulations including 178/2002, 767/2009, and 1831/2003.
More related reading
03 · Category
Industry Trends4 stats
01
CBD/CBG products comprised 7% of pet supplement sales in 2023 (industry segmentation)
02
E-commerce accounted for 25% of pet product sales in 2023 (channel trend supporting supplements)
03
Subscription purchases accounted for 12% of pet product buyers in 2023 (channel trend supporting recurring supplements)
04
“Veterinarian formulated” appeared on 31% of top-selling pet supplement labels in 2024 (label trend)
Interpretation
Industry Trends Interpretation
In the pet supplements industry, evidence of the shifting trends is clear as CBD and CBG made up 7% of 2023 sales while e commerce reached 25% and subscriptions grew to 12% of pet product buyers, and by 2024 veterinarian formulated claims appeared on 31% of top label products.
report visual · Key figures
Pet supplements show measurable adoption and efficacy signals
Industry segmentation and channel trends indicate where pet supplement demand is coming from, while multiple controlled studies report percent improvements across common health outcomes.
7%
CBD/CBG products comprised 7% of pet supplement sales in 2023 (industry segmentation)
25%
E-commerce accounted for 25% of pet product sales in 2023 (channel trend supporting supplements)
12%
Subscription purchases accounted for 12% of pet product buyers in 2023 (channel trend supporting recurring supplements)
31%
“Veterinarian formulated” appeared on 31% of top-selling pet supplement labels in 2024 (label trend)
41.3%
In a controlled trial, hemp-derived cannabidiol (CBD) reduced seizure frequency by 41.3% in dogs with idiopathic epileps
30%
In a controlled trial, liposomal curcumin reduced paw swelling by 30% in dogs with osteoarthritis compared with placebo
source-verifiedgrandviewresearch.com · rfom.com · packagedfacts.com · pubmed.ncbi.nlm.nih.gov2024
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Lars Eriksen. (2026, February 13). Pet Supplements Industry Statistics. Gitnux. https://gitnux.org/pet-supplements-industry-statistics
MLA
Lars Eriksen. "Pet Supplements Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/pet-supplements-industry-statistics.
Chicago
Lars Eriksen. 2026. "Pet Supplements Industry Statistics." Gitnux. https://gitnux.org/pet-supplements-industry-statistics.
Sources & references
28 datasets cited across this report · attribution is report-level
+15 additional datasets cited (not shown individually)